Details of the Drug
General Information of Drug (ID: DM83L5Y)
| Drug Name |
RIP
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
beta-D-Ribopyranose; Ribose(Pyranose Form); 7296-60-8; UNII-49X539P7H4; CHEBI:27476; 49X539P7H4; (2R,3R,4R,5R)-oxane-2,3,4,5-tetrol; b-Ribopyranose; 115794-07-5; beta-D-Ribopyranose (9CI); 1ogd; 1drk; 2dri; 1drj; Ribopyranose, beta-D-; SCHEMBL625216; AC1L9B91; CHEMBL1159662; CTK4A9488; ZINC4097544; DB04286; 1577-EP2301533A1; 1577-EP2292630A1; 1577-EP2316459A1; 1577-EP2305808A1; 1577-EP2281563A1; C08353; 1577-EP2270015A1; 31308-EP2311817A1; 31308-EP2308858A1; 31308-EP2274983A1; 31308-EP2311816A1; 31308-EP2292088A1
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 150.13 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | -2.5 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 4 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


